Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04796415 · ClinicalTrials.gov registry record · NA

DEMA-Pro Intervention for Seniors With Subjective Cognitive Decline and Living at Home

A NA study of Subjective Cognitive Decline, sponsored by Indiana University.

Completed
Registry status
NA
Development phase
49
Enrollment target
1
Study location

NCT04796415: Completed NA study of Subjective Cognitive Decline, sponsored by Indiana University.

NCT04796415 is a NA study of Subjective Cognitive Decline that has completed, run by Indiana University. The registered enrollment target is 49 participants, below the 77-participant average among 6 other Subjective Cognitive Decline trials with a reported enrollment target (36% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04796415, a NA study of Subjective Cognitive Decline, has completed, sponsored by Indiana University.

COMPLETED
Registry status
NA
Development phase
49 participants
Enrollment target
1
Study location

Study Summary

More than 4.4 million patients receive home health services following discharge from the hospital or rehabilitation facility. A substantial number (70%) are older adults with subjective cognitive decline (SCD), an early clinical sign of Alzheimer's disease and related dementia. SCD is associated with diminished activity performance, poor quality-of-life and other adverse health outcomes (e.g., depressive symptoms). Home health patients with SCD often require more time, structure, and guidance to complete tasks and adjust to new skills and environments. Support is especially important during this high-risk period of transition between care settings. We propose a new home health care delivery model in partnership with Kindred at Home (KAH), a division of Humana that encompasses 400 programs across 40 states. DEMA-Pro builds on five preliminary studies that demonstrated high feasibility, acceptability, and positive preliminary effects on health outcomes (physical function, mood, and QoL). DEMA-Pro will be refined for delivery by home health services staff to patients with SCD and their informal caregivers. The overall goal of this research will be to conduct a pragmatic cluster randomized controlled trial (RCT) of DEMA-Pro to improve outcomes in-home health service patients with SCD. In the current R61 pilot phase, we will establish the trial's organizational structure and processes and pilot test DEMA-Pro in 4 home health services sites. In a subsequent trial, we plan to conduct a full pragmatic RCT in a group of Kindred KAH sites comparing DEMA-Pro to usual care. Consistent with the spirit of a pragmatic trial, we will use existing data sources including electronic Medicare OASIS (Outcome and Assessment Information Set) data, and QoL to characterize the cohort and measure outcomes. Thus, the focus of the pilot phase will be to ensure all processes are in place to conduct the subsequent RCT. Aim 1. Establish the organizational infrastructure and programmatic processe

Primary Outcome

Change in Physical Function measured by the Outcome and Assessment Information Set Data of Instructive Activities of Daily Living Scale (OASIS-D, IADLs Scale M1800s ).The ADL/IADL composite score ranges from 0 (total independence) to 9 (totally dependent/unable to complete). Higher score represent greater dependence.

Interventions

  • BEHAVIORAL the DEMA-Pro intervention

Study Locations (1)

Indiana

  • Kindred at Home - Indianapolis

Trial Details

FieldValue
Enrollment Target 49 participants
Start Date 2021-05-01
Est. Completion 2022-08-31
Phase NA
Indiana University

890 total trials

What the finished NCT04796415 record still lists

NCT04796415 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 49 participants, a relatively small participant target, below the 77-participant average among 6 other Subjective Cognitive Decline trials with a reported enrollment target (36% lower).

The record links to 1 condition, with Subjective Cognitive Decline appearing as the primary indexed condition, and to 1 intervention - of which the DEMA-Pro intervention is the first listed.

NCT04796415 reports a single indexed study location in Indiana.

Frequently Asked Questions

What is clinical trial NCT04796415 about?

NCT04796415 is a clinical study titled "DEMA-Pro Intervention for Seniors With Subjective Cognitive Decline and Living at Home". More than 4.4 million patients receive home health services following discharge from the hospital or rehabilitation facility. A substantial number (70%) are older adults with subjective cognitive decline (SCD), an early clinical sign of Alzheimer's disease and related dementia. SCD is associated wit...

What is the current status of trial NCT04796415?

This trial is currently completed. It is a NA study. The enrollment target is 49 participants. The study started on 2021-05-01. Estimated completion is 2022-08-31.

What conditions does trial NCT04796415 study?

This clinical trial studies the following conditions: Subjective Cognitive Decline.

What interventions are being tested in trial NCT04796415?

The interventions under investigation include: the DEMA-Pro intervention (BEHAVIORAL).

Who is sponsoring clinical trial NCT04796415?

This trial is sponsored by Indiana University, which has 890 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04796415 being conducted?

This trial has 1 study location across Indiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Subjective Cognitive Decline

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02704858 · 49 participants · Phase 1

    Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma

  • NCT03516708 · 49 participants · Phase 1

    Epacadostat (INCB024360) Added to Preoperative Chemoradiation in Patients With Locally Advanced Rectal Cancer

  • NCT03692429 · 49 participants · Phase 1

    alloSHRINK - Standard cHemotherapy Regimen and Immunotherapy With Allogeneic NKG2D-based CYAD-101 Chimeric Antigen Receptor T-cells

  • NCT04329494 · 49 participants · Phase 1

    PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT04796415, the US trial registry maintained by the National Library of Medicine. NCT04796415 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.